INTRODUCTION
In drug-induced thrombocytopenia occurring as a result ofquinine or quinidine ingestion, IgG antibodies are formed, which, in the presence of the drug, cause blood platelet destruction (1, 2) . An antigen that causes lymphocytes of these patients to proliferate is formed by interaction of the drug, platelet membranes, and a plasma factor (3) . Platelets from patients with Bernard-Soulier syndrome, in which platelet glycoproteins lb and Is are deficient (4) , do not react with these drugdependent antibodies (5) and also do not possess the components required for formation of an antigenic stimulus (3) . These glycoproteins have also been implicated in the ability of platelets to react with Factor VIII (6) . We therefore examined the relationship between Factor VIII and drug-dependent antibodies by studying whether platelet damage by these antibodies occurs normally in platelet-rich plasma (PRP)1 from patients with von Willebrand's disease (vWd) (Factor VIII deficiency). We have also examined whether Factor VIII participates in formation of the antigenic stimulus that causes lymphocyte proliferation in patients sensitive to the drugs.
IAbbreviations used in this paper: PF3, platelet factor 3; PRP, platelet-rich plasma; vWd, voI1 Willebrand's disease; VIII:C, Factor VIII coagulant activity; VIIIR:Ag, Factor VIII-related antigen.
METHODS
Patient material. Blood was obtained from four patients fulfilling the diagnostic criteria of vWd (7) . They all had < 10% of the normal coagulation activity of Factor VIII (VIII:C) (8) . Von Willebrand factor detected by ristocetininduced agglutination of formalin-fixed platelets (9) was 0%. VIIIR:Ag was undetectable by immunoelectrophoretic assay (10) . Platelet-associated VIIIR:Ag (11) was undetectable when measured on three patients. Blood was also obtained from a patient with hemophilia A (0% VIII:C, 105% von Willebrand factor, 141% VIIIR:Ag), from two patients with hemophilia B (normal VIII levels, but 0 and 10% Factor IX), and from a patient on anticoagulant warfarin therapy whose levels of Factors II, VII, IX, and X were reduced to <20% normal.
Sera with antiplatelet activity. Quinineor quinidinedependent antibody-containing sera were obtained from seven patients fulfilling the diagnostic criteria ofdrug-induced thrombocytopenic purpura (1) . Antibodies not dependent on drugs were obtained from a patient after multiple transfusions and from another with idiopathic thrombocytopenia. An antiplatelet serum was raised in rabbits by immunization with human platelets, which had been washed six times. All sera were heated at 56°C for 30 min.
Methods. Procedures for blood collection and for preparation of platelet-rich plasma (PRP) were as described (3). Antiplatelet antibody was detected by the ability of sera to increase the rate ofplatelet factor 3 (PF3) availability (12, 13) . 0.1 ml serum was incubated at 37°C for 30 min with 0.8 ml PRP (platelet count adjusted to 3 x 101'/liter) and 0.1 ml either 0.15 M NaCl, 0.01 M Tris-HCl, pH 7.4, or quinine or quinidine hydrochlorides at a final concentration of 39 ,uM. 0.1 ml kaolin suspension (50 mg/ml) was added, and after 1 min, 0.1 ml was removed and added to a tube containing 0.1 ml 0.02 M CaCl2 and 0.1 ml Russell's viper venom (1:10,000 dilution, Wellcome Research Labs, Beckenham, England) and clotting time recorded. Platelet aggregation in an aggregometer (Payton Associates Ltd., Scarborough, Canada) and [14C]serotonin release were measured as described (14) . High molecular weight VIIIR:Ag (270 U/mg protein), containing von Willebrand factor, was purified as described (15) . Lymphocyte transformation was measured by incorporation of [methyl-3H]thymidine into DNA (3). Statistical significance of results was estimated using an unpaired t test on an electronic calculator (CS-365P) (Sharp Corp., Osaka, Japan).
RESULTS
Antibody-induced PF3 availability. When PRP from vWd patients was substituted for normal PRP, significantly less PF3 was made available by seven drug-dependent antibody sera (P < 0.001) ( Fig. 1 ). When purified VIIIR:Ag was added to PRP from vWd patients at 1 U/ml (the normal concentration of VIIIR: Ag in plasma), the mean results for PF3 availability in the presence of drug and drug-dependent antibody sera increased significantly (P < 0.001) to levels obtained with normal PRP, while having no effect on clotting times obtained in controls with normal human serum ( Fig. 1 ). Addition of VIIIR:Ag to normal PRP did not significantly alter the PF3 availability with drug-dependent antibody sera.
The decreased response of PRP from patients with Results are the mean difference in clotting times (±SD) obtained in the presence of drug compaired with samples in its absence in at least nine tests. Only some of the seven drug-dependent antibody sera examined were tested with each vWd patient.
In some samples VIIIR:Ag (1 U/ml) was added (cross-hatched bars). (B) results for other human antiplatelet antibody-containing antisera (H) and rabbit antiplatelet serum (R). The reduction in clotting time is the difference between that obtained with test and normal sera.
vWd to antibodies was specific for quinine and quinidine-dependent antibody sera. PRP from all vWd patients responded normally to an antiplatelet antiserum raised in rabbits and to two human sera containing antiplatelet antibodies unrelated to drugs ( Fig. 1 ). PRP from a patient with hemophilia A, two patients with hemophilia B, and a patient on anticoagulant warfarin therapy responded normally to the drug-dependent antibodies. This suggests that low levels of VIIIR:Ag, but not of VIII:C or of coagulation Factors II, VII, IX, or X prevent platelet damage by drug-dependent antibodies.
Antibody-induced platelet aggregation' and [14C]serotonin release. Four of the antibodies caused platelet aggregation and [14C]serotonin release in normal PRP in the presence of the appropriate drug. Both of these platelet responses were significantly (P < 0.01) reduced in PRP of patients with vWd ( either response. Normal PRP and vWd PRP did not differ significantly in their response to an idiopathic thrombocytopenia antibody (Fig. 2 ). Thus platelet aggregation and the release reaction induced specifically by drug-dependent antibodies also required VIIIR:Ag.
Specific lymphocyte transformation in the presence of sera deficient in coagulation factors. An earlier report (3) has demonstrated that lymphocytes from patients sensitive to quinine or quinidine, but not from normals, incorporate [methyl-3H]thymidine when cultured with normal platelets or platelet membranes and the appropriate drug. The cultures always contained pooled normal human serum.
When patients' lymphocytes were cultured with autologous platelets and quinine in the presence of sera from patients with vWd, transformation was markedly reduced in comparison with that obtained in cultures containing normal sera (Fig. 3) (P < 0.001). Sera from patients with either hemophilia A or B supported transformation to levels similar to those of normals. Addition of purified VIIIR:Ag to cultures containing vWd serum restored their ability to be transformed by platelets and quinine. This effect of VIIIR: Ag was specific for the platelet-drug stimulus and was not a nonspecific enhancement of lymphocyte transformation because transformation by pokeweed mitogen, or in saline controls, was similar in cultures containing either normal or vWd serum and was not significantly changed by addition of VIIIR:Ag (Fig. 3) . 
DISCUSSION
These results suggest that VIIIR:Ag is involved in the interaction of the platelet and drug-dependent antibodies. Shulman (2) suggested in 1958 that drugdependent antibodies may be directed against a complex of the drug and a factor from plasma with a special affinity for the platelet. Our findings that platelet damage, measured by three criteria, was markedly reduced in the absence of VIIIR:Ag, and was restored to normal levels by the addition of purified VIIIR:Ag, but was not affected by the absence of VIII:C or by reduction in levels of coagulation Factors II, VII, IX, or X, suggest that this plasma factor is VIIIR:Ag. Indeed VIIIR:Ag has a special affinity for platelet membranes, mediating platelet adhesion to the vessel wall (16) . The requirement for VIIIR:Ag in platelet attack by drug-dependent antibodies has probably remained unobserved until now because ofthe use in antibody detection tests of platelets and sera containing VIIIR:Ag. The platelet components, glycoprotein lb and Is, required for von Willebrand factor reaction with platelets (6) are also necessary both for interaction of drugdependent antibodies with platelets (5) and for forma-Factor VIJI-related Antigen and Drug-dependent Antiplatelet Antibodies tion of an antigen which caused transformation of lymphocytes of patients with drug-induced thrombocytopenia (3) . This suggests that these glycoproteins are more than simply a receptor for a drug-antibody complex and actually form part of the antigen. Our demonstration that VIIIR:Ag is also required for formation of the lymphocyte-transforming complex suggests that reaction of glycoproteins lb and Is with VIIIR:Ag is involved in forming the drug-induced antigen. The manner in which these components interact with quinine or quinidine to produce an antigen remains unclear.
